Nytyka (Nintedanib)

Nintedanib, the active ingredient in Nytyka, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in adult patients. GNH USA supplies Nytyka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nytyka is a tyrosine kinase inhibitor used in fibrotic lung disease and certain lung cancers. - Idiopathic pulmonary fibrosis: slows disease progression and preserves lung function. - Systemic sclerosis‑associated interstitial lung disease: reduces decline in forced vital capacity. - Non‑small cell lung cancer: used in combination therapy to inhibit tumor growth and angiogenesis.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may be accompanied by loss of appetite. - Vomiting: occasional episodes, usually related to gastrointestinal irritation. - Abdominal pain: cramping or discomfort in the stomach area. - Decreased appetite: reduced desire to eat, potentially leading to weight loss. - Elevated liver enzymes: mild increases in ALT/AST observed in routine labs.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring medical attention. - Major bleeding events: gastrointestinal or intracranial hemorrhage. - Arterial thromboembolism: clot formation in arteries causing ischemia. - Intestinal perforation: rare but life‑threatening bowel rupture. - Severe hypertension: marked increase in blood pressure. - Pneumonitis: inflammatory lung reaction presenting with cough and dyspnea.

Before initiating Nytyka, clinicians should assess baseline organ function and risk factors. - Liver function monitoring: check ALT/AST and bilirubin regularly during therapy. - Bleeding risk assessment: evaluate for anticoagulant use or coagulopathy. - Cardiovascular evaluation: monitor blood pressure and manage pre‑existing hypertension. - Renal impairment caution: adjust use in severe kidney disease. - Pregnancy and lactation: avoid use due to unknown safety; discuss contraception. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Nytyka may interact with several drug classes; careful review is required. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure. - Potent P‑gp/BCRP inhibitors (e.g., verapamil): can raise plasma concentrations. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Moderate P‑gp inhibitors (e.g., amiodarone): require dose observation. - NSAIDs or antiplatelet agents: monitor for additive bleeding tendencies.